复星医药作为国内创新型国际化医药企业,坚持创新驱动,加快创新成果转化。2025年,公司2款1类新药获批并新增进入国家医保目录,其中枸橼酸伏维西利胶囊5月首次获批,9月新增适应症获批,芦沃美替尼片5月获批,且二者均年底新增进入医保谈判目录。数据显示,2025年Q3枸橼酸伏维西利胶囊在城市实体药店销售额29万元,芦沃美替尼片在Q2-Q3合计卖出291万元,新医保目录落地后销量有望提升。此外,复星医药...
Source Link复星医药作为国内创新型国际化医药企业,坚持创新驱动,加快创新成果转化。2025年,公司2款1类新药获批并新增进入国家医保目录,其中枸橼酸伏维西利胶囊5月首次获批,9月新增适应症获批,芦沃美替尼片5月获批,且二者均年底新增进入医保谈判目录。数据显示,2025年Q3枸橼酸伏维西利胶囊在城市实体药店销售额29万元,芦沃美替尼片在Q2-Q3合计卖出291万元,新医保目录落地后销量有望提升。此外,复星医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.